Table 1.

Demographics

Patient	Gender	Diagnosis	Tumor volume (cm3)	Pre-SIRT FLR	SIRT treatment	Post SIRT tumor volume	Post SIRT FLR	Change in FLR
1	F	Metastatic colorectal	35	625	SIRTEX–right lobe	21	1096	+ 275
2	F	Metastatic neuroendocrine	109	240	SIRTEX–right lobe and segment 4 (staged)	41	420	+ 180
3	M	HCC	1150	656	SIRTEX–right lobe	136	819	+ 163
4	M	HCC	998	920	SIRTEX–left lobe	21	1126	+ 206
5	F	Metastatic colorectal	33	490	SIRTEX–right lobe	9	936	+ 446
6 (Figure 1 and 2)	M	HCC	1695	560	TheraSpheres–two treatments right lobe/segment 4	63	1469	+ 909
7	M	HCC	508	1350	TheraSpheres–right lobe	306	1524	+ 174
8	M	Metastatic colorectal	22	347	SIRTEX–right lobe	5	493	+ 146
9	F	HCC (Fibrolamellar)	350	1250	TheraSpheres–bilobar split treatment	20	1127	− 123*

Volumes calculated in cm³

*Due to bilobar treatment, some of the SIRT dose was likely given to the FLR resulting in a reduction in overall FLR